ObvioHealth Discusses Benefits of BYOD ePRO Models in Long-Term Clinical Trials

As an industry-recognized VRO (Virtual Research Organization), ObvioHealth highlights the benefits of BYOD ePRO models in transforming the landscape of long-term follow-ups.

Long-term patient follow-ups can be as challenging as they are crucial to driving patient centricity in clinical research. Through follow-ups, study teams can get in-depth insights into the efficacy of a therapeutic process under development over time, including improved long-term benefits and delayed side effects.

But engaging participants in a trial for the long-term can encourage dropout, thus leading to a lower participant retention rate. In addition, in-clinic follow-up techniques fail to foster patient engagement.

A study by NAP (National Academies Press) reveals that participant dropout rates in trials (phase III) can often be substantially high (sometimes even over 30%), resulting in expensive delays for study teams. On average, recruiting one participant for a trial can cost around $6,533. The outlay for replacing patients is even higher.

According to a study published in Applied Clinical Trials magazine, the LTFU (loss to follow-up) rate more than triples 1-2 years after a trial begins, which affects each touchpoint of the study process–from participants and study teams to sponsors. Citing this research, ObvioHealth marks the importance of leveraging BYOD (Bring Your Own Device) ePRO in addressing long-term drop-outs and LTFU.

According to the company, with many healthcare trials conducted today needing long-term follow-ups, study teams must leverage dynamic ePRO solutions to ensure improved patient retention and lowered LTFU rates.

Moreover, when more than 81% of US citizens use smartphones today and are more likely to operate them reliably than provisioned devices, it makes sense to introduce participants’ personal devices in healthcare research wherever possible. The result is significantly shortened trial timelines and more cost-effective clinical research that can yield more accurate patient data through simplified ePRO collection.

Additionally, such an ePro model can help life science and pharmaceutical industries design better patient-centric trials that make study participation more convenient and engaging.

ObvioHealth adds that by allowing patients to use technologies they are more acquainted with, the BYOD ePRO system ensures better participant compliance, thereby potentially minimizing the bias and burden associated with traditional follow-up processes.

A survey by Clinical Ink conducted on 155 patients with chronic pain found that 45% of the participants would prefer BYOD, compared to 15% preferring a provisioned device.

Further, BYOD ePRO can help trial teams increase the follow-up frequency without significantly burdening the subjects. Enabling teams to get a more frequent data stream at their fingertips for real-time analysis, BYOD ensures improved contact with participants, thus leading to streamlined safety monitoring.

ObvioHealth claims that whether a clinical trial is hybrid or fully decentralized, its augmented BYOD ePRO can address pain points and streamline each step of the data capture and rating process–from symptom documentation to patient-reported outcomes delivery. Integrating best-in-class AI with the real-time features and ease-of-use of intuitive ePRO, this single, unified system benefits subjects, sponsors, and study teams by delivering more precise endpoints for bolstered trail efficacy.

Interested parties can learn more about ObvioHealth by visiting https://www.obviohealth.com/.

ObvioHealth USA, Inc.

545 West 25th Street
20th Floor
United States

comtex tracking